PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.79

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.88M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 76.39B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 18.65B
SMMT Summit Therapeutics PLC

N/A

USD 17.01B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.70% 21% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.70% 21% F 13% F
Trailing 12 Months  
Capital Gain -75.00% 24% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.00% 24% F 10% F
Trailing 5 Years  
Capital Gain -91.15% 30% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.15% 30% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -26.33% 17% F 9% A-
Dividend Return -26.33% 17% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.69% 91% A- 67% D+
Risk Adjusted Return -98.66% 7% C- 4% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.